HomeCompareVACC vs O

VACC vs O: Dividend Comparison 2026

VACC yields 40.00% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VACC wins by $197.6K in total portfolio value
10 years
VACC
VACC
● Live price
40.00%
Share price
$5.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$231.9K
Annual income
$39,181.04
Full VACC calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — VACC vs O

📍 VACC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVACCO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VACC + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VACC pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VACC
Annual income on $10K today (after 15% tax)
$3,400.00/yr
After 10yr DRIP, annual income (after tax)
$33,303.88/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, VACC beats the other by $28,966.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VACC + O for your $10,000?

VACC: 50%O: 50%
100% O50/50100% VACC
Portfolio after 10yr
$133.1K
Annual income
$22,141.89/yr
Blended yield
16.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

VACC
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
0.8
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VACC buys
0
O buys
0
No recent congressional trades found for VACC or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVACCO
Forward yield40.00%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$231.9K$34.2K
Annual income after 10y$39,181.04$5,102.74
Total dividends collected$174.4K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: VACC vs O ($10,000, DRIP)

YearVACC PortfolioVACC Income/yrO PortfolioO Income/yrGap
1← crossover$14,700$4,000.00$10,818$608.16+$3.9KVACC
2$21,224$5,495.33$11,787$741.68+$9.4KVACC
3$30,125$7,415.26$12,946$911.00+$17.2KVACC
4$42,071$9,836.48$14,345$1,127.94+$27.7KVACC
5$57,854$12,838.17$16,056$1,409.05+$41.8KVACC
6$78,403$16,499.54$18,171$1,777.83+$60.2KVACC
7$104,788$20,897.28$20,820$2,268.21+$84.0KVACC
8$138,226$26,102.79$24,188$2,929.90+$114.0KVACC
9$180,082$32,179.61$28,533$3,837.11+$151.5KVACC
10$231,869$39,181.04$34,235$5,102.74+$197.6KVACC

VACC vs O: Complete Analysis 2026

VACCStock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Full VACC Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this VACC vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VACC vs SCHDVACC vs JEPIVACC vs KOVACC vs MAINVACC vs STAGVACC vs ADCVACC vs NNNVACC vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.